Xinfu Sues Xinfa For Patent Infringement
This article was originally published in PharmAsia News
Xinfu Pharm, the number one global supplier of calcium D-pantothenate with an annual output of 6,500 tons, now faces serious competition from Shandong Xinfa Pharmaceutical. The latter's output ballooned dramatically from 600 tons to 5,000 tons over the last two years. Xinfu has filed a lawsuit against Xinfa, claiming that its rival's meteoric rise stems from infringement of Xinfu's patented technology. In response, Xinfa issued a legal declaration stating that the new technique was developed by its own researchers based on Japan Daiichi's patent. Insiders reveal that the case boils down to the world's two largest calcium D-pantothenate producers slugging it out for the lucrative market. (Click here for more - Chinese language)
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.